TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17886213
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with ACE‐i + ARB
Study: 14996515
Drug: Epinastine hydrochloride
Normalized name: Epinastine Hydrochloride
DrugBank: Epinastine (DB00751)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Epinastine hydrochloride 0.05% ophthalmic solution, 1 drop/eye BID for 8 weeks
Study: 14996515
Drug: Levocabastine hydrochloride
Normalized name: Levocabastine Hydrochloride
DrugBank: Levocabastine (DB01106)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levocabastine hydrochloride 0.05% ophthalmic suspension, 1 drop/eye BID for 8 weeks
Study: 7884660
Drug: TY‐11345 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: TY‐11345 (40 mg single dose)
Study: 7884660
Drug: TY‐11345 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TY‐11345 (20 mg single dose)
Study: 7884660
Drug: TY‐11345 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: TY‐11345 (60 mg repeated dose)
Study: 7884660
Drug: TY‐11345 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: TY‐11345 (40 mg single dose with food)
Study: 7884660
Drug: TY‐11345 (20,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TY‐11345 (20, 40, and 80 mg single doses)
Study: 7884660
Drug: TY‐11345 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: TY‐11345 (all doses)
Study: 2889217
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg terfenadine twice daily
Study: 2569998
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg chlorpheniramine three times daily
Study: 30176758
Drug: Intrauterine misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine misoprostol (400 mg) added to oxytocin
Study: 26300016
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) 0.3 g.kg(‐1) body weight
Study: 23273683
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural infusion (PERI group)
Study: 16849754
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g EPA
Study: 16849754
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g EPA
Study: 12845488
Drug: Furosemide 40
Normalized name: furosemide 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide 40 mg/day orally for 5 days
Study: 30939537
Drug: Transdermal 17Î²-estradiol
Normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal 17Î²-estradiol (t-E2)
Study: 30341117
Drug: Single FMT
Normalized name: [18F]FMT
DrugBank: 6-[18F]-Fluoro-L-m-tyrosine (DB17621)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single FMT dose
Study: 30341117
Drug: Five daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Five daily FMT doses
Study: 30341117
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no FMT dose)
Study: 20560847
Drug: Internet-based clinician-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based clinician-assisted cognitive behavioural treatment program (the Panic program)
Study: 16900557
Drug: Biologic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic treatments
Study: 16900557
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy or placebo
Study: 16195955
Drug: Later sessions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Later sessions (regardless of drug condition)
Study: 17398191
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antihypertensive therapy)
Study: 15021311
Drug: IFN alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN alfa-2b 3 mIU daily plus RBV 800 mg/d
Study: 15021311
Drug: IFN alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN alfa-2b 3 mIU thrice weekly plus RBV 800 mg/d
Study: 7984652
Drug: 10% naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% naproxen gel
Study: 2257959
Drug: 10% ketoprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% ketoprofen gel
Study: 519265
Drug: Fibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic therapy (streptokinase)
Study: 519265
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no fibrinolytic therapy)
Study: 23676183
Drug: CETP inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: CETP inhibitor
Study: 19396791
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg intracameral bevacizumab (Group 1)
Study: 19396791
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg intracameral bevacizumab (Group 2)
Study: 16525571
Drug: Eptifibatide plus
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide plus unfractionated heparin
Study: 30146709
Drug: BTL UNISON
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTL UNISON device treatments (4 sessions)
Study: 30146709
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatments)
Study: 17984433
Drug: 3.86% glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.86% glucose, low pH/high GDP dialysis solution (pH 5.5)
Study: 10446037
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of alpha-tocopherol
Study: 7796786
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day zinc gluconate for 3 months
Study: 30430745
Drug: Mechanical bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical bowel preparation (MBP) using either two bottles of sodium phosphate or 2-L polyethylene glycol
Study: 22976604
Drug: No mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: No mechanical bowel preparation (no-MBP)
Study: 28561902
Drug: Rapid BDM
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid BDM (ready-to-dilute solution, 50 mL admixture, infusion time 10 minutes)
Study: 28561902
Drug: Original BDM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original BDM (lyophilized product requiring reconstitution, 500 mL admixture, infusion time 30 or 60 minutes)
Study: 28561902
Drug: Both BDM
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both BDM formulations
Study: 24621834
Drug: Intravenous levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous levosimendan for 24 hours
Study: 17473298
Drug: Intravenous levosimendan
Normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous levosimendan
Study: 21656668
Drug: high in
Normalized name: High incidence antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: high in iTFA (10.2 g/2500 kcal)
Study: 19303414
Drug: lamivudine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: lamivudine (100 mg daily)
Study: 28342988
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (IG) received culinary-based workshops, monthly newsletters, and telephone calls incorporating Motivational Interviewing.
Study: 28342988
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) received monthly nutritional brochures from the American Institute for Cancer Research.
Study: 26056183
Drug: Paclitaxel with
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel with bevacizumab (90 mg/m2)
Study: 26056183
Drug: Nab-paclitaxel (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nab-paclitaxel (150 mg/m2)
Study: 26056183
Drug: Ixabepilone (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixabepilone (16 mg/m2)
Study: 16760927
Drug: Placebo augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo augmentation
Study: 1867231
Drug: Cholesterol-lowering therapy
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-lowering therapy
Study: 15064002
Drug: Medication (stimulants)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (stimulants)
Study: 10838323
Drug: Triphasic norgestimate/EE-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic norgestimate/EE-containing oral contraceptive (ORTHO TRI‐CYCLEN(R))
Study: 7936332
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg/day (Group A)
Study: 7936332
Drug: Amlodipine 10
Normalized name: amlodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10 mg/day and hypocaloric diet (Group B)
Study: 2678584
Drug: Serum PAI‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum PAI‐1 levels above 550 ng/ml
Study: 2678584
Drug: Serum PAI‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum PAI‐1 levels below 550 ng/ml
Study: 26304854
Drug: Concurrent radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiotherapy with S-1 plus cisplatin (CRSC)
Study: 26304854
Drug: Concurrent radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiotherapy with cisplatin alone (CRC)
Study: 20601207
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol 400 mcg
Study: 20601207
Drug: Ipratropium 80
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium 80 mcg
Study: 30951521
Drug: Octreotide-LAR (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide-LAR (20 mg, intramuscular injections every 28 days for 3 years)
Study: 30951521
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% sodium chloride solution, intramuscular injections every 28 days for 3 years)
Study: 20122366
Drug: quetiapine 300
Normalized name: quetiapine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine 300 mg/d
Study: 20122366
Drug: quetiapine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine 600 mg/d
Study: 20122369
Drug: lithium 600
Normalized name: lithium 600 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: lithium 600 to 1800 mg/d
Study: 2152752
Drug: alfa‐2b recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfa‐2b recombinant Interferon (3,000,000 i.m. three times a week for three months, repeated after three months) + surgery therapy
Study: 2152752
Drug: alfa‐2b recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfa‐2b recombinant Interferon (3,000,000 i.m. three times a week for three months, repeated after three months) + chemotherapy
Study: 2152752
Drug: surgery therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: surgery therapy
Study: 6941699
Drug: Central nervous
Normalized name: CENTRAL NERVOUS SYSTEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central nervous system prophylaxis (cranial radiation and intrathecal chemotherapy)
Study: 8579005
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (IT)
Study: 2970203
Drug: Paroxetine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine (30 mg daily)
Study: 2880767
Drug: Pivampicillin 350
Normalized name: pivampicillin 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivampicillin 350 mg
Study: 2202709
Drug: Metronidazole 400
Normalized name: metronidazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 400 mg
Study: 28705547
Drug: Closed incision
Normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed incision negative pressure therapy (ciNPT)
Study: 26461064
Drug: Nurse-led medicines'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led medicines' monitoring using the West Wales ADR Profile for Mental Health Medicines
Study: 19819677
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (30 g/ethanol/d for 28 days)
Study: 19819677
Drug: Gin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gin (30 g/ethanol/d for 28 days)
Study: 19624858
Drug: Both intervention
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both intervention groups (weekly group‐based exercises and a home program for twelve months)
Study: 14751699
Drug: Active corticosteroid
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active corticosteroid inhaler (doubling the dose)
Study: 14751699
Drug: Placebo corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo corticosteroid inhaler (no change in dose)
Study: 11751734
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (n=11)
Study: 11751734
Drug: Double the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double the ACE inhibitor dose (n=11)
Study: 8111223
Drug: Brofaromine (85
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brofaromine (85 mg/day)
Study: 8111223
Drug: Imipramine (87
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (87 mg/day)
Study: 3024864
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (Tilade) 4 mg four times daily
Study: 30587918
Drug: Generic irbesartan
Normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic irbesartan 150 mg
Study: 17932102
Drug: Fibrinolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic therapy (FT)
Study: 31749275
Drug: Liraglutide 0.6
Normalized name: liraglutide 0.6 mg/0.1 mL (18 mg/3 mL) SUBCUT PEN INJECTOR (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 0.6 mg subcutaneous on the evening before surgery and 1.2 mg after induction of anaesthesia
Study: 30880176
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg glepaglutide
Study: 30880176
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg glepaglutide
Study: 28630086
Drug: Cognitive stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive stimulation therapy specifically adapted for Parkinson's‐related dementias (CST‐PD), involving 30 min sessions delivered at home by the study companion three times per week over 10 weeks.
Study: 25224595
Drug: Oral cryotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cryotherapy (OC) only
Study: 12921454
Drug: Guided imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided imagery and relaxation therapy
Study: 10763948
Drug: Standardized multicomponent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized multicomponent behavioral therapy plus standard medical treatment (SMBT)
Study: 10763948
Drug: Standard medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medical treatment alone (SMT)
Study: 6145368
Drug: Pancuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.1 mg/kg intravenously
Study: 3730522
Drug: Free combination
Normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free combination
Study: 3730522
Drug: Atenolol tablet
Normalized name: Atenolol Tablets
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol tablet
Study: 3730522
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination ('Tenoret 50')
Study: 3730522
Drug: Chlorthalidone tablet
Normalized name: Chlorthalidone Tablets
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone tablet
Study: 30073285
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide (50% nitrous oxide and 50% oxygen inhaled for 40 minutes)
Study: 30073285
Drug: Placebo (50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (50% nitrogen and 50% oxygen inhaled for 40 minutes)
Study: 28392509
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (25-mg agomelatine)
Study: 15497661
Drug: Test and
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test and Reference formulations
Study: 23939841
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (passive decompression via open operative ports)
Study: 18250271
Drug: KAI-9803 (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAI-9803 (1.25 mg)
Study: 18250271
Drug: KAI-9803 (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAI-9803 (5.0 mg)
Study: 16488388
Drug: Credible placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Credible placebo treatment (PLA)
Study: 12741878
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance back extension exercise on a 45 degrees Roman chair once weekly for 12 weeks, one set of 8‐20 dynamic repetitions to volitional exhaustion using hand‐held metal plates for additional resistance
Study: 10834689
Drug: Gabexate mesylate
Normalized name: mesylate
DrugBank: Gabexate (DB12831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabexate mesylate (2 mg/kg/hr)
Study: 10834689
Drug: Saline (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (2 mL/hr; control group)
Study: 1352563
Drug: Naftopidil 25
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 25 mg
Study: 1352563
Drug: Naftopidil 50
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 50 mg
Study: 30568303
Drug: APVAC1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APVAC1 vaccine derived from unmutated antigens
Study: 30568303
Drug: APVAC2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APVAC2 vaccine targeting neoepitopes
Study: 29857876
Drug: Horticultural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horticultural therapy program (10 sessions, once weekly)
Study: 27097076
Drug: A. dracunculus
Approvals — FDA: no, EMA: no, PMDA: no
Description: A. dracunculus (1000 mg) before breakfast and dinner for 90 days
Study: 20467301
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise prescription throughout the study
Study: 20467301
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise prescription after completing cancer treatment
Study: 7857350
Drug: Pidotimod (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pidotimod (800 mg orally, twice daily) plus antibiotic (amoxycillin plus clavulanic acid: 1 g twice daily)
Study: 196167
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment with 'strong' sleeping pills followed by 'weak' sleeping pills
Study: 30145946
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg once daily for 45 days
Study: 17535867
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy for 6 months
Study: 15302778
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) treatment
Study: 15302778
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of UFH (>5000 U, or up to 90 U/kg)
Study: 15302778
Drug: UFH weight‐indexed
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH weight‐indexed dose
Study: 12670035
Drug: IVECG signal
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVECG signal conducted from the guide wire (group G)
Study: 12670035
Drug: Group G
Normalized name: Prostaglandin group G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group G (guide wire)
Study: 8200218
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mifepristone 12 hours before surgical procedure
Study: 8200218
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mifepristone 24 hours before surgical procedure
Study: 29049072
Drug: SGB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SGB with 5 mL of normal saline
Study: 25594610
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate (0.1%) cream (BMVc)
Study: 25594610
Drug: Tacrolimus (0.1%)
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus (0.1%) ointment (TACo)
Study: 27958255
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance correlation with vitB12
Study: 17437361
Drug: Tigecycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigecycline (100 mg IV initial dose then 50 mg IV every 12 h)
Study: 28114928
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene orientation (OHO) + supragingival treatment + simulation of using photodynamic therapy (PDT)